Kaleido Biosciences Inc. (KLDO) to Offer Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Kaleido Biosciences Inc. (KLDO) Prices 5.25M Share Common Offering at $11.50/Sh
February 4, 2021 5:56 AM ESTKaleido Biosciences, Inc. (NASDAQ: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $11.50 per share. In addition, Kaleido has granted the underwriters a 30-day option to purchase up to an additional 787,500 shares of its... More
